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Abstract 
Promensil is a plant-based postmenopausal medication containing phytoestrogens that 
mimic the structure of estrogen. Cell line treatments with Promensil were performed to study if it 
had any influence on the cell cycle regarding specific cell cycle proteins. Furthermore, T47D 
cells were administered MPP, an estrogen receptor-α specific antagonist, to verify if the 
Promensil antiproliferative mechanism is estrogen receptor-α mediated. Due to a variety of 
issues, it was not possible to make any conclusions about the effects of Promensil on the cell 
cycle. Promensil effects were still seen in cells treated with MPP, therefore it was determined 
that the antiproliferative effector pathway of Promensil is not estrogen receptor-α mediated, thus 
refuting the hypothesis.  
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Introduction 
1.1 Breast Cancer 
Breast cancer is a disease that more commonly affects women than men. The disease 
occurs when breast cells rapidly grow out of control, beginning in the ducts or lobules of the 
breasts and possible spreading to the rest of the body (Breast Cancer). As women age, the risk of 
breast cancer increases. This is likely due to the change of hormones in menopausal and post-
menopausal women. Breast cancer is the second most commonly diagnosed cancer among 
women in the United States, after skin cancer. The average age of diagnosis is 61 for women, but 
the death rate from the disease has decreased over time due to advances in medicine and 
therapies (Breast Cancer; Chalasani).  
Breast cancer cells can develop in a variety of ways that must be identified to prescribe 
the proper treatment. Mutations in HER2, human epidermal growth factor receptor 2, or BRCA1, 
breast cancer type 1 susceptibility protein, may cause uncontrollable proliferation of breast 
cancer cells (HER2 Status; BRCA1 gene). However, about two-thirds of all breast cancers are 
positive for hormone receptors, either estrogen receptor (ER) or progesterone receptor (PR) 
positive. ER positive breast cells grow in response to estrogen, whereas PR positive cells grow in 
response to the hormone progesterone. Estrogen and progesterone bind to their cell receptors and 
signal for an increase in cell proliferation. Hormone responsive cancers are the most common 
forms of breast cancer, especially in older woman (Breast cancer hormone receptor status, 2018). 
1.2 Estrogen and its receptors 
Estrogens are a group of steroids that are responsible for key areas of growth and 
development in women. It is responsible for changes to a woman’s body during puberty, 
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including menstrual cycles, breast development, bone growth, and other metabolic processes. 
The most abundant estrogen is 17 β-estradiol (E2), which is produced in the ovaries and placenta 
(Estrogen, 2011).  
Studies have shown that ERs regulate cell proliferation and development in both men and 
women. There are two main ERs: ER-α and ER-β. These receptors are encoded by different 
genes on different chromosomes and vary in quantity, depending on the type of cell in which 
they are found (Lee et al. 2012). ER-α is more commonly present in breast, ovary, bone, liver, 
male reproductive organs, and prostate cells, whereas ER-β is more commonly found in bladder, 
colon, and immune system cells, with some overlap between the two. ER-α acts as a growth 
receptor for E2 more often than ER-β, which typically has more anti-proliferative effects. 
(Paterni et al. 2014).  ER positive breast cancer cells can have both estrogen receptors, ER-α and 
ER-β. Yet, ER-α is more likely responsible for increased proliferation in breast cancer cells, than 
ER-β (Lee et al. 2012). 
1.3 Menopause 
As women age, their bodies change, and their ovaries begin to stop producing estrogen, 
eventually causing a women’s menstrual cycle to end. During menopause, women may 
experience a vast number of symptoms and other health risks associated with a loss of estrogen. 
Some symptoms of menopause may include hot flashes, sleep problems and night sweat, and 
vaginal and urinary changes. Menopause also increases the risk of long-term health problems, 
like osteoporosis and cardiovascular disease. To alleviate the symptoms of menopause, many 
women resort to taking estrogen supplements, either hormone therapy with progestin or plant-
based estrogen substances (The Menopause Years).  
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1.3.1 Hormone Replacement Therapy 
The Food and Drug Administration (FDA) approved the use of estrogen as a supplement 
to alleviate symptoms of menopause in 1942. Since then, estrogen has become widely used as 
hormone replacement therapy (HRT) to relieve the side effects of menopause. Currently, studies 
are being conducted to look at HRT as a means of decreasing the risk of breast cancer in women. 
Yet, some studies have shown trends that HRT is associated with increased risk of breast cancer. 
Despite this, it is still commonly used to treat menopausal symptoms (Shook 2014). Despite the 
associations of HRT with breast cancer and other diseases, it is still relatively unknown if HRT 
has any effect on breast cancer or other diseases. The American College of Obstetricians and 
Gynecologists (ACOG) explain some of the risks of hormone replacement therapy. They say that 
estrogen therapy may cause uterine cancer, deep vein thrombosis, or stroke. In addition to 
systemic estrogen therapy, some woman may choose to take over-the-counter estrogen 
supplements that may be plant based to supplement the loss of estrogen (The Menopause Years).  
1.4 Phytoestrogens 
Phytoestrogen are compounds, structurally similarly to estrogen, that are derived from 
plants. These compounds can be found in commonly consumed foods, including soy products, 
peas, beans, flaxseeds, red wine, and tea. A review by Bilal et al. (2014) describes the role 
phytoestrogens have on ERs. Phytoestrogens typically possess a lower binding affinity to ERs 
than estrogen, but one study showed that the phytoestrogens genistein and daidzein have a higher 
binding affinity to ER-β than estrogen (Kuiper et al. 1998). Other studies have shown that some 
phytoestrogens can interact with cell growth factors and pathways (Choi and Kim et al. 2008). 
Particularly, one study showed that phytoestrogen genistein was able to inhibit cell cycle 
regulator cyclin D1 at high concentrations in breast cancer cells (Lavigne et al. 2008). Others 
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have shown that phytoestrogens may inhibit estrogen synthesis all together in estrogen receptor 
breast cancer cells (Bilal et al 2014).  
Some phytoestrogens are being studied as Selective Estrogen Receptor Modulators 
(SERMs), which are synthetics that can bind to the ER and act as antagonists. Tamoxifen, for 
example, was the first approved chemopreventive by the Food and Drug Administration (FDA) 
and a SERM. It is metabolized by the body and broken down into smaller molecules capable of 
binding to ERs to prevent proliferation. Like tamoxifen, some phytoestrogens have been shown 
to have antiproliferative properties, whereas others act as agonists for estrogen, and are 
considered to possibly be natural SERMs. It is also suggested that some phytoestrogens may be 
able to bind to ER-β preventing stimulation of ER-α and proliferation (Oseni et al. 2008).  
1.4.1 Isoflavones 
Isoflavones are a class of phytoestrogens that are widely present in many food sources. 
Soybeans, for example, are rich in isoflavones. The four isoflavones are genistein, daidzein, 
biochanin A, and formononetin. Genistein and daidzein are derived from biochanin A and 
formononetin. Isoflavones are converted in the gastrointestinal tract into molecules that mimic 
estrogens (Barnes 2004).  
Genistein and daidzein are the most common isoflavones and share a similar phenolic 
ring structure to estrogen. Both can be found in red clover and soybeans. Genistein has been 
extensively studied and has shown to have a high binding affinity to both ER-α and ER-β. It has 
been shown in many studies that genistein treatment may inhibit the growth of multiple cancer 
cell lines, including breast cancer. The effect of genistein is determined by the concentration 
metabolized by the body. Concentrations less than 1µM act as an agonist for estrogen, inducing 
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cell growth, whereas concentrations greater than 5µM act as an antagonist, repressing cell 
growth, as shown in MCF-7 breast cancer cells (Sarkar and Li 2002).  
1.5 Promensil 
Promensil is an over the counter woman’s phytoestrogen supplement containing 
isoflavones from red clover. It was created to relieve symptoms of menopause and to provide 
dietary support. The Promensil website says that their double strength 80mg tablets contain 
isoflavones genistein, daidzein, formononetin and biochanin (About Promensil).  
There is limited information on the Promensil website and some studies have looked 
further into the effects of Promensil. One study by van de Weijer and Barentsen (2002) showed 
that treatments by Promensil were able to decrease hot flashes in menopausal women. In a 
randomized placebo-control study, the researchers gave participants either two Promensil tablets 
at 40 mg or two placebo tablets. Their urine was sampled to measure the total isoflavone 
excretion between the two groups. The researchers found that both groups of women had hot 
flash symptoms at baseline, but the Promensil treatment group had fewer hot flashes at the end of 
the study. They found that hot flashes had been reduced by 44% (van de Weijer and Barentsen 
2002).  
Another study by Setchell et al. (2001) investigated dietary supplements containing 
isoflavones, including Promensil. Their goal was to determine the content of the supplements 
using liquid chromatography and mass spectrometry to compare their results with the claims of 
the manufacturer. They found that Promensil contains 41.7 mg isoflavones per capsule, which is 
consistent with the manufacturer’s claim that each single strength tablet contains 40 mg (Setchell 
et al. 2001).  
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1.6 Cell Cycle  
The cell cycle is a tightly regulated process that allows for growth and division. There are 
four stages of the cell cycle: G1, when the cell is active and stimulated by many growth factors; 
S, when the DNA of a cell is replicated; G2 when the rest of the cell’s organelles divide and 
prepare for division; and mitosis: the final division of the cell (Weinberg, R. A., 2014). Each part 
of the cell cycle is monitored by a series of proteins that act together to function as checkpoints. 
These checkpoints help to ensure that the cell is replicating without error to prevent mutated cells 
from accumulating in the body tissues (Weinberg, R. A., 2014). 
1.6.1 Cyclin D1, p21, and PCNA 
One group of proteins responsible for regulating the cell cycle are cyclins. Cyclins help to 
regulate the action of cyclin-dependent kinases (CDKs) (Weinberg, R. A., 2014). When CDKs 
bind to cyclins, the CDKs are activated and are able to then phosphorylate other protein such as 
retinoblastoma protein (pRB) (Weinberg, R. A., 2014). Cyclin D1 specifically binds to CDK4 
and CDK6 (abbreviated as CDK4/6) (Weinberg, R. A., 2014). In particular, cyclin D1 influences 
the cell’s passage through the R checkpoint (Weinberg, R. A., 2014). The R checkpoint is the 
checkpoint that controls the cell’s entrance into S phase (Weinberg, R. A., 2014). Cyclin D1 has 
also been seen by Zwijsen, R. M. in 1997 to bind to ERs independently of estrogen, providing 
another pathway by which cyclin can influence cell proliferation (Zwijsen, R. M., 1997). They 
did this by looking at the expression levels of proteins whose expression is promoted by the ERs 
and showing that the expression levels were raised by the presence of cyclin D1 even in the 
absence of estrogen (Zwijsen, R. M., 1997). There is also evidence that cyclin D1 acts to 
promote proliferation in this way and not to halt the cell cycle (Zwijsen, R. M., 1997). Many 
studies have shown that an overexpression of cyclin D1 leads to an early onset of tumors 
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(Elsheikh et al. 2008). It has also been shown by Takako Sakamoto et. al. in their 2010 paper that 
when MCF-7 cells are exposed to phytoestrogens that, except for glycitein, cyclin D1 
concentration is transiently increased leading to cell proliferation (Sakamoto, T. et al., 2010) 
While cyclin D1 serves as an important promoter for the cell cycle, it must be kept in balance to 
ensure that cells don’t divide inappropriately as this could lead to cancer. 
While cyclin D1 acts as an oncogene (a gene that if mutated can encourage cell 
proliferation and tumorigenesis), p21 is a CDK inhibitor and normally acts a tumor suppressor. 
p21 arrests the cell cycle in G1 by inhibiting the action of CDK2/4 when the cell is undergoing 
oxidative stress, when DNA damage has occurred, and when activated by extracellular signal 
molecules (Abbas, T., & Dutta, A, 2009) p21 may also prevent apoptosis in the cell, inhibiting 
with caspase-3 (Abbas, T., & Dutta, A, 2009).  
Once in S phase, PCNA (proliferating cell nuclear antigen) acts as a DNA clamp 
(Kelman, Z, 1997). This means that it is responsible for supporting DNA replication by binding 
to DNA polymerase. This ensures that DNA polymerase cannot fall off the DNA molecule and 
that the genome is fully replicated. In cancer cells, PCNA has been seen to be overexpressed in a 
study run by Corinne Cayrol, Martine Knibiehler, and Bernard Ducommun in 1998. They 
showed that expression of wild-type p21 in P53 deficient DLD1 human colon cancer cells inhibit 
DNA synthesis and results in cell cycle arrest in G1 and G2 (Cayrol, C, et al., 1998). They also 
showed that these effects were still seen when the p21 protein was mutated such that it couldn’t 
interact with CDKs, but not when it was mutated in a way that prevented it from binding with 
PCNA (Cayrol, C, et al., 1998). This implies that the interaction of p21 with PCNA, not any of 
the CDKs, is what results in the cessation of DNA synthesis and the G1 and G2 cell cycle arrest 
(Cayrol, C, et al., 1998). 
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The effects of phytoestrogens on the cell cycle are still unclear. Some studies have shown 
that cyclin D1 is overexpressed in estrogen-responsive breast cancers. Choi et al. 2008 found that 
daidzein decreased the amount of MCF-7 breast cancer cells in G1 at 10uM by 31%. 
Additionally, they were able to show that daidzein was able to decrease the expression of Cyclin 
D in MCF-7 cells as well (Choi et al. 2008). 
1.7 ER- Alpha and MPP  
There is still no definitive answer on how exactly Promensil treatments are able to affect 
ER-α resulting in the repression of the transcription of certain genes, although ER-α is a major 
transcriptional regulator. Through microarray analysis, global gene expression profiling has 
shown that when estradiol (E2) is bound to ER-α it upregulates certain cell cycle proteins 
resulting in increased proliferation (Stossi 2009). Further research using ER-α specific 
antagonists has been done in an attempt to elucidate this mechanism. A study on estrogen-
regulated genes revealed MPP serves as a selective antagonist that represses the inflammatory 
function of interleukin-6 promoter activity through ER-α, in response to local cell proliferation 
(Harrington et al. 2003). Increased proliferation from steroidal stimulation was fully inhibited by 
the addition of MPP resulting in the inhibition of ER- α mediated proliferation in the MCF-7 
breast cancer cell line. This study aims to see the same effect in T47D breast cancer cells.  
1.8 T47D Breast Cancer cell line 
T47D cells are a breast cancer cell line derived from 54-year-old female with infiltrating 
ductal carcinoma breast cancer. They were isolated from mammary glands and are adherent 
epithelial cell with both estrogen and progesterone hormone receptors that also express the 
WNT7B oncogene (T47D).  
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1.9 Evaluating the effects of Promensil on T47D cells with and without active ER-α  
This project is a continuation of the phytoestrogen project at Worcester Polytechnic 
Institute (WPI). One previous project has shown that the proliferation of T47D is inhibited at 
higher concentrations of Promensil-derived phytoestrogens (Gergel et al. 2010). Another project, 
using T47D cells that turn off ER-β in the presence of tetracycline, showed no difference in the 
number of T47D cells affected by Promensil (Wambach 2018). This indicates that Promensil 
does not work through ER-β. Therefore, in continuation of past projects, T47D breast cancer 
cells will be treated with MPP to determine if Promensil antiproliferative effects are ER-α 
mediated. One study was done at the Department of Molecular and Integrative Physiology of the 
University of Illinois that designed ER-α selective antagonists by adding basic side chains (BSC) 
to pyrazole complexes in seven different configurations. They found that the antagonist with the 
highest affinity for ER-α was methyl-piperidino-pyrazole (MPP), over 200-fold compared to ER- 
β (Sun 2002). 
1.10 Summary 
In summary, this project will investigate two aspects of Promensil effects on T47D cells. 
Specifically, the presence or absence of certain cell cycle proteins and if the inhibition of T47D 
cell proliferation is ER-α mediated. To examine cell cycle effects, the expression levels of p21, 
cyclin D1, and PCNA will be quantified. These proteins are involved in the regulation and 
activity of the cell cycle. As Promensil has been shown to reduce proliferation in these cells, it is 
expected that being exposed to Promensil would result in these cells expressing a higher level of 
p21, a lower level of cyclin D1, and a lower level of PCNA. As previously stated, in the presence 
of E2 ER-α upregulates several cell cycle proteins, increasing proliferation. MPP, an ER-α 
specific antagonist, will be used in conjunction with Promensil to verify whether or not the 
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antiproliferative components of Promensil act through ER-α as anticipated. Proliferation of 
T47D cells has been observed to be signaled through ER-α (Stossi, 2009). It is predicted that 
when cells are also treated with MPP the antiproliferative effects of Promensil will not be 
observed. This would indicate that Promensil’s antiproliferative effects are ER-α mediated. 
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Methods 
2.1 Promensil Extraction: 
Two Double strength (80mg) Promensil tablets (Lot number 18943A) were obtained over 
the counter. Tablets were crushed into a fine powder in a mortar and pestle and added to 80% 
methanol (100 mL) in a 250 mL round bottom flask. The flask was attached to a reflux 
condenser for one hour in a 70℃ water bath. The solution was then vacuum filtered using a 
Whatman 3mm filter and stored at -20℃. Extract was filter-sterilized an additional time before 
use. 
2.2 Cell Maintenance: 
T47D cells were obtained from ATCC. Cells were grown in regular growth media: 
DMEM/F12 media with 10% Fetal Bovine Serum, and 1% penicillin/streptomycin (Pen/Strep) 
(100X). Insulin was added to media to a final concentration of 1.7µM directly to flask. Cells 
were plated in T25 or T75 flasks, depending on usage, and incubated at 37℃ and 5% carbon 
dioxide. Cells were maintained and split when the cell’s confluence reached about 90%. 
2.3 Cell Plating and Synchronization: 
T47D cells were plated in 12 well plates at 200,000 cells per well in regular growth 
media (1mL/well + 1.7µM Insulin/well). After 24 hours, media was changed to 1mL/well + 
1.7µM Insulin/well serum-free starving media: DMEM/F12 and 1% Pen/Strep. Starving media 
was used to remove any growth factors that stimulate proliferation of the cells so that the cells 
would be synchronized in terms of their cell cycles. 24 hours following the starving media, 
media was changed to treatment 1mL per well + 1.7µM Insulin/well media: Phenol red-free 
DMEM (PHRED), 10% charcoal-stripped FBS, and 1% Pen/Strep. PHRED media was used to 
limit the estrogenic effects on the cells caused by the phenol red structure that is similar to 
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estrogen. At the same time the PHRED media was added, 100nM 𝛽-estradiol (E2) and Promensil 
was added to the cells. Cells were treated for 48 hours and incubated at 37℃ and 5% carbon 
dioxide before being harvested. 
2.4 MPP Concentration Assay:  
T47D cells were plated in 12 well plates at 200,000 cells per well in regular growth 
media (1mL per well + 1.7µM Insulin/well). Cell plating and synchronization protocol was 
followed. 10mg anhydrous MPP (Methyl-piperidino-pyrazole hydrate) dihydrochloride, a 
specific antagonist for ER-𝛼 (Sigma Aldrich) was obtained and reconstituted in DMSO. Working 
dilutions were made to have final in-well concentrations of 1µM, 100nM, and 1nM from a 
10mM MPP stock solution. All wells received 10µL of 10µM 𝛽-Estradiol (E2) for final in well 
concentrations of 100nM E2. Each of the concentrations were added to the plate in triplicates, 
along with DMSO control wells with no MPP. Cells were treated for 48 hours and incubated at 
37℃ and 5% carbon dioxide before being harvested.  
2.5 E2, Promensil, & MPP Treatment: 
T47D cells were plated in 6 well plates (3) with a 150,000 cells/well seeding density in 
regular growth media (3mL per well + 1.7µM Insulin/well). The reduction in seeding density 
was done to reduce the cell contact inhibition that was seen in the 12 well plates. Cell plating and 
synchronization protocol was followed; however, cells were left in regular growth media for 48 
hours instead of 24 hours. Treatments for each well respectively were as follows: no treatment, 
0.8% Methanol + 1% DMSO, 100nM E2 + 1% DMSO, 1% Promensil extract + 1% DMSO, 
100nM E2 + 100nMMPP, 1% Promensil extract + 100nM MPP. Cells were treated for 48 hours 
and incubated at 37℃ and 5% carbon dioxide before being harvested.  
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2.6 Cell Harvesting: 
After treatment, media was aspirated from cells and washed with 1 mL cold PBS on ice. 
For cell counting, cells were scraped off the plate into 1 mL cold PBS using a rubber spatula and 
samples were placed in 1.5 mL microfuge tubes. Samples were spun down at 5,000 x g for 1 
minute, resuspended in 300 µL PBS and live cell concentrations were counted with the 
Cellometer Auto T4. For immunoblotting, cells were lysed in the -80°C freezer for 10 minutes 
and in the first well of each treatment, cells were scraped into 200 µL PBS then transferred to the 
next duplicate well to pool replicates and transfer to 1.5 mL microfuge tubes. Lysates then 
incubated for 10 minutes on ice. Then were vortexed and incubated for an additional 10 minutes 
on ice. Lysates were then spun down at 13,000 x g for 5 minutes. Supernatants were pipetted to 
new microfuge tubes and stored in the -20°C until ready to use.  
2.7 Gel Electrophoresis Immunoblotting: 
Immunoblotting was used to determine the presence of proteins of interest. Concentration 
of protein from lysed cells was determined using the NanoDrop Lite Spectrophotometer (Thermo 
Scientific). Either 10µg or 15µg of protein was combined with 6x denaturing Sample Buffer 
(Appendix A). Samples were vortexed and proteins were denatured on a 95°C hot plate for 5 
minutes. Samples were put on ice for 2 minutes. Samples were loaded on 12% SDS 10 well Mini 
Protean Precast Gels in quantities normalized to total protein. 1x SDS running buffer (Appendix 
A) was added to gel apparatus (Bio-Rad) and gel ran at a constant 250 V for about 30 minutes or 
until dye had reached the black line on the bottom of the gel. Following gel electrophoresis, filter 
paper and Polyvinylidene difluoride (PVFD) were cut to fix approximately the size of the gel. 
Filter paper was soaked in transfer buffer (Appendix A), drained, and layered on Semi-Dry 
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Electroblotter (Owl Separation Systems). Precast gel was broken up and cut using a razor to 
remove well fringes and dye runoff. Gel was put in transfer buffer and placed on top of filter 
papers of Semi-Dry Electroblotter, protein side up. A Millipore Immobilon-P PVDF membrane 
(Lot number K5JN4531L; Pore size: 0.45µm) was soaked in methanol and then soaked in 
transfer buffer after absorbing methanol. PVDF was placed on top of gel, followed by 3 more 
filter papers. Gel was transferred at amperage equivalent to 0.8-1milliamps/ cm2 of gels on 
apparatus for 1 hour. Following transfer, PVDF membranes were cut in half using a razor and 
put in blocking solution of 1% low fat instant dried milk and 1x TBS-T (Appendix A) for 30 
minutes at room temperature on rocking platform. Primary antibody dilutions of 1:1000 of 
Cyclin D1 (A-12 sc-8396), PCNA (F-2 sc-25280), p21 (F-5 sc-6246), and caspase-3 p17 (sc-
271028) (Santa-Cruz Biotechnology) were made in 1x TBS-T and kept cold. Blocking buffer 
was discarded and 3mL of each primary antibody were added to plastic pouches along with each 
replicate membrane and kept overnight at 4°C on a rocking platform. Following priming, 
immunoblots were washed 3 times for 5 minutes in 1x TBS-T at room temperature on rocking 
platform. Secondary antibody (BP-HRO sc-516102) (Santa-Cruz Biotechnology) was added to 
1x TBS-T at a dilution of 1:5000. Immunoblots were covered in 3 mL of secondary solution for 
1 hr. at room temperature on rocking platform. Blots were washed again 3 times for 5 minutes in 
1x TBS-T at room temperature on rocking platform.  Blots were covered and stained with 
colorimetric 1-Step Ultra TMB Blotting-Solution (Thermo Scientific) for 5-30 minutes or until 
bands had developed. Reaction was stopped by added 2x MilliQ water. Protocol for using Pierce 
1-Step Ultra TMB Blotting-Solution was obtained from ThermoFisher Scientific. Blots were 
imaged using the ChemiDoc XRS Gel Photo Documentation System (BioRad).  
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Gels following transfer were stained with GelCode Blue (Thermo Scientific) to ensure an 
optimal transfer. Gels were washed 2 times for 5 minutes with MilliQ water at room temperature 
on rocking platform. GelCode Blue was added to cover the gel and left to stain at room 
temperature on rocking platform for 15-60 minutes. Gel was de-stained in three, 5-minute 
washes with MilliQ water.  
2.8 Immunoblot Analysis: 
The intensities from three trials were averaged together and the standard error was found 
using Excel. The intensities were then graphed. 
2.9 Stripping: 
Used immunoblots were stripped of their antibodies to be re-probed with other 
antibodies. Stripping buffer (Appendix A) was prepared to pH 2.2. PVDF membrane washed 2 
times in stripping buffer for 7 minutes each. Membrane was washed 2 times in 1x PBS 
(phosphate-buffered saline) for 10 minutes each. Membrane was then washed 2 times in 1x TBS-
T for 5 minutes each. Membrane was then processed according to immunoblotting protocol from 
blocking step with primary antibody of interest. Protocol was obtained from AbCam (Abcam, 
2019). 
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Results & Discussion 
3.1 MPP Concentration Assay 
Synchronized T47D breast cancer cells were treated with 3 different concentrations of 
ER-𝛼 specific antagonist, MPP (Methyl-piperidino-pyrazole). E2 was added to all cells, left to 
incubate for 48 hours and then harvested for counting. See figure 1 below: 
 
 
Figure 1: Optimizing MPP concentrations for cell treatment. Concentrations listed are for final 
in-well concentrations. Error bars represent standard error (n=2) 
DMSO Control wells yielded the highest average live cell counts. Concentrations of 1μM 
MPP showed a 38% reduction and 100nM MPP showed a 39% reduction in proliferation in 
comparison to DMSO control average live cell count. Therefore, 100nM MPP was deemed most 
effective at inhibiting estrogen-stimulated proliferation and was used for all future experiments.  
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The MPP concentration at 1nM was too low and lost efficacy, indicated by the 
comparative increase in cell proliferation to the other two concentrations with only a 14% 
reduction in cell proliferation. 
Initially, there was some difficulty in getting the plated cells to remain viable. It was 
suspected that MPP alone may have had cytotoxic effects on the T47D breast cancer cell line. 
Upon further investigation, it was determined that MPP alone was not cytotoxic because cells 
remained viable in all subsequent experiments involving MPP. After cell harvesting, compare the 
cell counts or do the same with another unrelated/healthy cell line.   
3.2 E2, Promensil, & MPP Treatments 
Synchronized T47D breast cancer cells were treated with different combinations of E2, 
Promensil, and MPP. After 48 hours, cells were harvested and counted for treatment effects on 
cell proliferation. See figure 2 below:  
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Figure 2: Measuring the impact on proliferation of T47D cells from E2, Promensil, and MPP 
combinations (Averaged from 3, 6 well plates). E2 and MPP final in-well concentrations were 
100nM. Error bars represent standard error (n=3) 
Wells containing Promensil were expected to induce antiproliferative effects and wells 
with E2 would induce proliferation of T47D cells (Singh, M., & Singh, N., 2010). It was 
hypothesized that upon addition of ER-𝛼 specific antagonist, MPP, in Promensil wells, 
antiproliferative effects would be mitigated, thus providing evidence that the effector pathway of 
the phytoestrogen supplement is ER-𝛼-mediated. E2 treatments with DMSO control induced the 
most proliferation as expected, whereas Promensil with DMSO control wells exhibited the most 
anti-proliferative effects with 31% inhibition of T47D cell line proliferation. MPP appeared to 
inhibit E2-mediated proliferation with 16% reduction in comparison to wells with E2 devoid of 
MPP. Wells incubated with Promensil and MPP still exhibited inhibition of T47D cell line 
proliferation, although not as drastic as Promensil with DMSO control, which yielded a 20% 
reduction in proliferation in comparison to no treatment average live cell count. An analysis of 
variance (ANOVA) test was done between the six conditions (P-value < 0.0000) and the data 
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was statistically significant. It was hypothesized that Promensil alone may have also had 
cytotoxic effects on the T47D breast cancer cell line similar to MPP. To certify this hypothesis, 
T47D cells could be plated at 1X105cells/well, in similar fashion to the E2, Promensil, & MPP 
Treatment protocol (Methods), with and without Promensil alone. In the case that Promensil 
effects are not estrogen receptor dependent, the same assay could be carried out in an unrelated 
or healthy cell line. Additionally, in further investigations a time course study with MPP could 
be done to determine the optimal time it should be added to cells, either before or after Promensil 
treatment.    
During cell treatments, micrographs of cells in representative wells for MPP, E2+MPP, 
and Promensil+MPP were taken. See figure 3 below: 
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Figure 3: Microscopy of T47D Breast cancer cell line treated with Promensil, E2 and MPP. 
Taken at 100X magnification.  
The majority of wells presented similar cell morphology and density as normally 
observed prior to treatment . Cells appeared to be spread out with incomplete attachment to the 
monolayer. This could be due to not allowing enough time in initial growth media (Methods) for 
attachment, the rate of media exchange was too fast, or perhaps during cell synchronization the 
serum-free media (Methods) was too harsh, thus preventing cells from thriving. As seen in figure 
5 above, the Promensil+MPP well exhibited much darker cells. Forty-eight hours after treatment, 
photographs of E2+MPP and Promensil+MPP wells revealed visual live/dead cell densities that 
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concur with the degree of proliferation in figure 2.  It was possible that the seeding density for 
these treatments were too high, therefore explaining the high amount of cell debris. It is 
recommended to initially plate 1*105 cells/well for all future related treatment combinations.  
3.3 Cell Cycle Immunodetection 
While antibodies for 3 cell cycle proteins were used, neither p21 nor cyclin D1 resulted in 
visible bands when blots were developed. P21 and cyclin D1 were chosen to provide data based 
on both an oncogene (cyclin D1) and a tumor suppressor (p21). PCNA was chosen because it is a 
transcription factor that should be active if the cell is actively dividing. The lack of bands in p21 
and cyclin D1 blots was possibly do to low protein concentration or low antibody affinity. The 
antibody to PCNA however, resolved quantifiable bands. 
 
 
Figure 4: A representative immunoblot for PCNA. PCNA has a molecular weight of 29kDa. 
(Negative=MeOH treatment, E2=Estradiol, P=Promensil). (n=3) 
Figure 4 above shows the bands from the PCNA immunoblots. There are clear bands for 
the negative control, the E2 positive control and the Promensil experimental sample. The bands 
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appear between 25kDa and 37kDa. It appears that the intensity of all three bands are very 
similar. In order to confirm this, the intensity was calculated and is shown in figure 5 below: 
 
 
Figure 5: Volume absorbance intensities measured for PCNA immunoblots (Averaged from 3 
different blots). Error bars represent standard error (n=3). 
The graph above shows that there was no significant change in PCNA band intensity 
between Negative, Positive (E2), and Promensil treatments. The negative control was slightly 
higher, but the sample population was too small to know if that difference was significant or not. 
An ANOVA was run and the calculated p value for this data set was 0.9925. This was far higher 
than 0.05 and so it must be considered as showing no significant change in band intensity 
amongst treatments. 
The data shown in Figure 5 above appears to show no change in the intensity of the bands 
when the cells were treated with E2 (positive control) or Promensil. It was expected that the cells 
treated with E2 would have a larger PCNA band intensity because an increase in PCNA 
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expression is associated with an increase in cell division (Singh, M., & Singh, N., 2010). The 
data that was collected appears to show that E2 had no effect on the volume of the bands 
resulting from the cells treated with E2. This discrepancy makes it difficult to come to any 
conclusions based on this data. It is possible that a positive change in band intensity would 
appear if more blots were run.  
It is likely that there was no intensity change in any of the PCNA bands because the cells 
were plated at too high a density in the 12-well plates. The wells were very confluent even right 
after the wells were plated. This left very little room for the cells to grow after they were treated. 
They had already reached the stationary phase, or possibly even the death phase in their growth 
curve. There was no difference in the intensity of the PCNA bands for the E2 treated samples 
because there simply wasn’t enough room to proliferate anymore. The T47D cell line has been 
shown to exhibit contact inhibition (Kim, S, et.al., 2004). This means that when these cells grow 
next to each other they will stop dividing (Ribatti, D., 2017). This would have happened almost 
immediately when these cells were plated, thus activating apoptosis and repressing cell 
proliferation even when E2 was added. 
 In conclusion, it was known that when T47D cells were treated with Promensil, the cells 
would show reduced proliferation. This led to the hypothesis that when T47D cells are treated 
with Promensil then they would show lower levels of PCNA when analyzed through a Western 
blot. However, the data collected was not enough to allow for this hypothesis to be supported or 
rejected. The data shows underlying issues with the experimental setup, such as too high a 
plating density, therefore conclusions cannot be drawn from the immunodetection data 
presented. Promensil is similar in molecular structure to E2 and when breast cancers are positive 
for hormone receptor expression, E2 is known to bind to ER- α, inducing cancerous cell 
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proliferation. With this information, it was hypothesized that when treated with Promensil and 
ER-α is bound by specific antagonist, MPP, T47D cells would not exhibit antiproliferative 
effects. Meaning, the antiproliferative effector pathway of Promensil involves or requires ER-α 
to function. However, the data refutes this hypothesis as antiproliferative effects were still 
observed in wells containing MPP and Promensil (figure 2).  
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Appendix A: Buffer recipes  
(All buffer recipes adapted from recipes found at Abcam, 2019) 
NP-40 buffer: 
20mM Tris HCl, pH 8.0 
137mM NaCl 
10% glycerol 
1% NP-40 
2mM EDTA 
Semi Dry Transfer Buffer: 
48mM Tris-base 
39mM Glycine 
0.04% SDS 
20% Methanol 
1x Running Buffer: 
25mM Tris-base 
190mM Glycine 
0.1% SDS 
Check pH and adjust to 8.3 
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6x Sample Buffer: 
16% β-mercaptoethanol 
30% Glycerol 
4% SDS 
0.6% bromophenol blue 
0.25M Tris-HCl 
Stripping Buffer pH 2.2:  
15g Glycine 
1g SDS 
10mL Tween-20 
1x TBST: 
For 1 L: 
100 mL of TBS 10x 
900 mL distilled water 
1 mL Tween 20 
 
